Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Checkpoint Inhibitors Spur Changes in Trial Design

    Cancer Discovery
    |October 11, 2017
    PubMed
    Summary

    Checkpoint inhibitors are driving numerous clinical trials. Novel trial designs and endpoints are being explored to improve efficiency, but rising costs pose challenges for smaller research institutions.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Brain Network Connectivity Predicts Survival in Diffuse Midline Glioma.

    Cancer discovery·2026
    Same journal

    First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.

    Cancer discovery·2026
    Same journal

    CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma.

    Cancer discovery·2026
    Same journal

    CDK8 inhibition induces Mediator trapping and impairment of the EWSR1::FLI1 transcriptional program in Ewing sarcoma.

    Cancer discovery·2026
    Same journal

    SEZ6-Targeted ADC Shows Preliminary Efficacy in Small Cell Lung Cancer.

    Cancer discovery·2026
    Same journal

    Nonprofit Acquires Abandoned Leukemia Drug Supply.

    Cancer discovery·2026

    Area of Science:

    • Oncology
    • Immunotherapy
    • Clinical Trial Design

    Background:

    • Checkpoint inhibitors have shown significant success in cancer treatment.
    • There is a growing interest in combining checkpoint inhibitors with other therapies.
    • Hundreds of clinical trials are currently investigating these combinations.

    Purpose of the Study:

    • To explore efficient methods for studying novel cancer immunotherapies.
    • To identify strategies for optimizing early-phase clinical trial designs.
    • To address the challenges posed by the increasing complexity and cost of clinical trials.

    Main Methods:

    • Investigating the use of novel endpoints in clinical trials.
    • Exploring the utility of new preclinical models for immunotherapy research.
    • Examining adaptive trial designs for early-phase studies.

    Main Results:

    • Researchers and regulatory bodies are actively exploring innovative approaches.
    • Novel endpoints, preclinical models, and adaptive designs are under consideration.
    • The increasing sophistication of trials presents resource challenges.

    Conclusions:

    • The field is advancing rapidly with new therapeutic strategies.
    • Optimizing clinical trial methodologies is crucial for efficient drug development.
    • Ensuring equitable participation in early-phase trials requires addressing cost and resource barriers.

    Related Experiment Videos